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Abstract
Background: The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced
prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic
stage in HER2-positive breast cancer patients enrolled in the ShortHER trial.
Methods: The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab
combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant
disease-free survival (DDFS) was calculated from randomization to distant relapse or death.
Results: A total of 1244 patients were included. Compared to anatomic stage, the prognostic stage downstaged
41.6% (n = 517) of patients to a more favorable stage category.
Five-year DDFS based on anatomic stage was as follows: IA 96.6%, IB 94.1%, IIA 92.4%, IIB 87.3%, IIIA 81.3%, IIIC
70.5% (P < 0.001). Five-year DDFS according to prognostic stage was as follows: IA 95.7%, IB 91.4%, IIA 86.9%, IIB
85.0%, IIIA 77.6%, IIIC 67.7% (P < 0.001). The C index was similar (0.69209 and 0.69249, P = 0.975).
Within anatomic stage I, the outcome was similar for patients treated with 9 weeks or 1 year trastuzumab (5-year
DDFS 96.2% and 96.6%, P = 0.856). Within prognostic stage I, the outcome was numerically worse for patients
treated with 9 weeks trastuzumab (5-year DDFS 93.7% and 96.3%, P = 0.080).
Conclusions: The prognostic stage downstaged 41.6% of patients, while maintaining a similar prognostic
performance as the anatomic stage. The prognostic stage is valuable in counseling patients and may serve as
reference for a clinical trial design. Our data do not support prognostic stage as guidance to de-escalate treatment.
Trial registration: EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278.
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Introduction
Advances in medical treatment have significantly im-
proved the prognosis of human epidermal growth factor
2 (HER2)-positive early breast cancer (BC) patients over
time and led to establish chemotherapy combined with
1 year of trastuzumab as the standard adjuvant treat-
ment [1].
The impact of prognostic/predictive biomarkers on the
outcome of patients treated with appropriate standard
systemic treatment has been considered by the Ameri-
can Joint Committee on Cancer (AJCC) Staging System
panel in the update of the breast cancer staging. Based
on the incorporation of biologic factors (histologic grade,
estrogen receptor, progesterone receptor, HER2, and
multigene panels) to the classic anatomic stage, the 8th
edition of the AJCC breast cancer staging system has in-
troduced prognostic stage, which was developed using
data from patients identified in the National Cancer
Database (2010–2011) and then validated in large co-
horts of patients from the MD Anderson Cancer Center
and the California Cancer Registry [2–7]. These studies
allowed to confirm the improved prognostic perform-
ance of the prognostic stage as compared to the ana-
tomic stage in the general breast cancer patients’
population. The most recently updated version of the
prognostic stage was released after the results of the val-
idation study highlighted that a proportion of patients
could not be assigned a specific prognostic stage [7].
Therefore, the prognostic staging system was refined to
include all the possible combinations of anatomic stages
and biomarkers [8]. As declared by the AJCC staging
panel, the actual prognostic stage will undergo frequent
updates, based on future validation studies in large data-
bases of patients treated with state-of-the-art therapies
[4, 6]. Several studies, all conducted in retrospective pa-
tient cohorts, have been reported in the last couple of
years, overall corroborating the prognostic stage as a
more accurate discriminator of breast cancer patients’
outcome as compared to the anatomic stage. However, it
has to be pointed out that many of these studies used
data from the National Cancer Database or the SEER
(Surveillance, Epidemiology, and End Results) registry
covering a period of time including years 2010 and 2011.
Considering the overlap between the National Cancer
Database and the SEER, these studies included data that
were previously used by the AJCC panel to develop the
prognostic score. Moreover, most of these studies, in-
cluding the main validation studies by the AJCC panel,
did not report detailed analysis of distinct breast cancer
subtypes, with no study specifically focused on HER2-
positive disease. Furthermore, even in the most robust
cohorts, exposure to trastuzumab was not reported or
not homogeneous among HER2-positive patients (litera-
ture review in Additional file 1) [7, 9–23]. This aspect is
a relevant caveat, since the assumption at the basis of
the adoption of the prognostic stage is that patients are
offered adequate systemic treatment based on biologic
characterization [2, 4, 6].
One of the major clinical needs for HER2-postive BC
patients is an accurate risk stratification to guide esca-
lated and de-escalated strategies to ensure the most ef-
fective treatment along with a more rationale resource
allocation [24]. One of the most important goals of sta-
ging is to help clinicians define a treatment plan [5];
therefore, the evaluation of outcome prediction by the
prognostic stage in HER2-positive patients cohorts
treated with standard therapy is a key step in order to
define its potential role as tool to guide de-escalated
therapeutic choices. For this kind of investigation, a ran-
domized trial testing de-escalated against standard treat-
ment represents the ideal setting.
In this study, we aimed to validate the prognostic stage
in HER2-positive BC patients treated with adjuvant
chemotherapy combined with 1 year or 9 weeks trastu-
zumab in the randomized ShortHER trial [25].
Methods
Patients
The ShortHER trial (NCT00629278) is a phase 3 trial of
adjuvant therapy that randomized 1253 patients with
HER2-positive early BC to anthracycline and taxane-
based chemotherapy combined with 1 year (long) or
9 weeks (short) trastuzumab. Study characteristics and
results are reported elsewhere [25].
Staging
In the present analysis, patients were classified according
to the anatomic stage, based on tumor size (T) and
nodal status (N), and to the prognostic stage that takes
into account T, N, estrogen receptor, progesterone
receptor, histologic grade, and HER2 status. The most
recent version of the 8th AJCC edition was used as ref-
erence [8]. Histologic grade, hormone receptor expres-
sion, and HER2 status were based on local pathology.
According to the AJCC staging manual, for the present
analysis, estrogen receptor and progesterone receptor
expression was classified as positive in case of staining in
> 1% of tumor cells.
Once the anatomic and prognostic stages were applied,
patients with discordant stage assignment were defined
as follows:
– Those patients moved to a more favorable stage
category with the prognostic stage as compared to
the anatomic stage were defined as downstaged;
– Those patients moved to a less favorable stage
category with the prognostic stage as compared to
the anatomic stage were defined as upstaged.
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Statistical analysis
Statistical analyses were performed using IBM SPSS v.24
and R project for Statistical Computing [26]. Distant
disease-free survival (DDFS) was calculated from
randomization until relapse at a distant site or death,
whichever first.
Kaplan-Meier method was used to estimate survival
curves. The log-rank test was used to compare stage cat-
egories. The Harrel concordance index (C index) was
calculated for each of the two staging systems. Differ-
ence between the C index of the anatomic and prognos-
tic stage models was tested by using “compareC”
package in R [26]. Cox proportional regression models
were used to calculate hazard ratios (HRs) and 95% con-
fidence intervals (CIs). The log-rank test χ2 statistic, and
its P value were used to explore the discrimination be-
tween groups. The significance level was P < 0.05. All
tests were two-sided.
Results
Stage classification
Complete data for classification according to the ana-
tomic and the prognostic stage were available for 1244
patients. Patients’ characteristics are reported in Table 1.
The comparison of anatomic and prognostic stage classi-
fications is summarized in Table 2.
The rate of concordance was 58.4% (n = 727 patients),
whereas 517 patients (41.6%) had a discordant stage cat-
egory assignment. All discordant cases were downstaged
by the prognostic stage:
 100% of anatomic stage IB patients (n = 40) were re-
classified as IA
 61.6% of anatomic stage IIA patients (n = 246) were
re-classified as IB (6.0%) or IA (55.6%);
 63.0% of anatomic stage IIB patients (n = 94) were
re-classified as IA (1.3%) or IB (81.7%);
 58.7% of anatomic stage IIIA patients were re-
classified as IB (19.0%) or IIA (39.7%);
 100% of anatomic stage IIIC patients (n = 66) were
re-classified as IIIA (13.6%) or IIIB (86.4%).
Among downstaged patients, the change was by one
stage down for 23.4% (n = 121), by two stages down for
71.8% (n = 371), and by three stages down for 4.8% (n =
25) of cases.
Survival analysis
Median follow-up was 6.1 years. Five-year DDFS rates
and their 95% confidence interval for stage categories ac-
cording to the anatomic and prognostic stage classifica-
tions are reported in Table 3, survival curves are shown
in Fig. 1.
Both models showed the ability to stratify patients
at different outcome (log-rank P < 0.001). The C index
was 0.69209 for the anatomic stage and 0.69249 for
the prognostic stage, with no significant difference
(P = 0.975). With prognostic stage, 58.9% of patients
were classified as stage IA and showed excellent out-
come after adjuvant chemotherapy and trastuzumab
(5-year DDFS 95.7%, 95%CI 94.2–97.3%). However,
within each of the stage categories, the outcome was
numerically inferior for the prognostic stage groups
(Table 3).
Table 4 shows Cox regression analysis for DDFS ac-
cording to anatomic and prognostic stage, with stage IA
as reference category. With anatomic stage, the progno-
sis of stage IB and IIA patients was not statistically
Table 1 Patients’ characteristics
Characteristics N (%)
Age, years
< 60 795 (69.3)
> 60 449 (36.1)
Histologic grade
1 8 (0.7)
2 363 (29.6)
3 857 (69.8)
Menopausal status
Premenopause 446 (35.9)
Postmenopause 797 (64.1)
Estrogen receptor (> 1% cut-off)
Negative 354 (28.5)
Positive 890 (71.5)
Progesterone receptor (> 1% cut-off)
Negative 495 (39.8)
Positive 749 (60.2)
Pathologic T stage
pT1 763 (61.4)
pT2 450 (36.2)
pT3 28 (2.3)
pT4 1 (0.1)
Pathologic lymph nodes stage
pN0 672 (54.0)
pN1mic 69 (5.5)
pN1 321 (25.8)
pN2 116 (9.3)
pN3 66 (5.3)
Arm
A Long 624 (50.2)
B Short 620 (49.8)
Abbreviation: N number
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different as compared to stage IA patients. With prog-
nostic stage, all stage categories showed significantly
worse outcome as compared to stage IA. We further ex-
plored the stage discrimination by focusing on stages I–
II and looking at the log-rank χ2 and its P value in paired
comparisons. For IB vs IA, the χ2 statistics was 0.014
(P = 0.906) for anatomic stage and 5.930 (P = 0.015) for
prognostic stage. For IIA vs IB, the χ2 statistics was
0.579 (P = 0.447) for anatomic stage and 0.263 (P =
0.608) for prognostic stage. For IIB vs IIA, the χ2 statis-
tics was 5.322 (P = 0.0.021) for anatomic stage and 0.165
(P = 0.686) for prognostic stage. A higher χ2 statistic in-
dicates a higher group separation. The results of the Cox
regression analysis and those of the paired log-rank tests
indicate that, for patients with stage I–II disease, the lar-
gest prognostic discrimination is between stage IIB and
previous stages for anatomic stage and between stage IB
and IA for prognostic stage.
Short vs long trastuzumab in stage I patients
Analyses comparing DDFS of stage I patients treated
with 9 weeks vs 1 year trastuzumab were conducted
(Fig. 2). The outcome of anatomic stage I patients (n =
509) was excellent irrespectively of trastuzumab duration
(5-year DDFS 96.2%, 95%CI 93.8–98.7% in the short arm
and 96.6%, 95%CI 94.4–99.0% in the long arm). Among
prognostic stage I patients (n = 872), those who received
9 weeks trastuzumab had a non-significant numerically
inferior DDFS (5-year DDFS 93.7%, 95%CI 91.4–96.2%
vs 96.3%, 95%CI 94.5–98.2%, log-rank P = 0.080; HR
1.60 95%CI 0.94–2.73, P = 0.083). When limiting the
analysis to patients with prognostic stage IA, the abso-
lute difference in 5-year DDFS was reduced to 1.5%
(95.0%, 95%CI 92.7–97.3% in the short arm vs 96.5%,
95%CI 94.5–98.5% in the long arm, log-rank P = 0.408;
HR 1.29, 95%CI 0.70–2.38, P = 0.409).
Discussion
This is the first study (i) evaluating the performance of
prognostic AJCC stage specifically for early HER2-
positive BC patients treated with adjuvant chemotherapy
and trastuzumab, (ii) evaluating the performance of
prognostic AJCC in a prospective randomized trial, and
(iii) validating the prognostic AJCC in a European pa-
tients’ cohort. Our findings show a similar prognostic
performance for prognostic and anatomic stage, despite
prognostic stage reallocated a substantial proportion of
patients (41.6%) to a more favorable stage category.
Table 2 Comparison of anatomic and prognostic stage classifications in patients enrolled in the ShortHER trial
AJCC prognostic stage
IA IB IIA IIB IIIA IIIB Tot
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
AJCC anatomic stage
IA 469 (100) 0 0 0 0 0 469 (37.7)
IB 40 (100) 0 0 0 0 0 40 (3.2)
IIA 222 (55.6) 24 (6.0) 153 (38.3) 0 0 0 399 (32.1)
IIB 2 (1.3) 92 (61.7) 0 55 (36.9) 0 0 149 (12.0)
IIIA 0 23 (19.0) 48 (39.7) 0 50 (41.3) 0 121 (9.7)
IIIB 0 0 0 0 0 0 0
IIIC 0 0 0 0 9 (13.6) 57 (86.4) 66 (5.3)
Tot 733 (58.9) 139 (11.2) 201 (16.2) 55 (4.4) 59 (4.7) 57 (4.6) 1244 (100)
Abbreviations: AJCC American Joint Committee on Cancer, N number
Table 3 Five-years DDFS rates by stage category according to the anatomic and prognostic stage classifications
Stage Anatomic stage Prognostic stage
N (%) 5-yr DDFS % (95% CI) N (%) 5-yr DDFS % (95% CI)
IA 469 (37.7) 96.6 (95.0–98.3) 733 (58.9) 95.7 (94.2–97.3)
IB 40 (3.2) 94.1 (86.4–100) 139 (11.2) 91.4 (86.6–96.4)
IIA 399 (32.1) 92.4 (89.7–95.2) 201 (16.2) 86.9 (82.2–91.9)
IIB 149 (12.0) 87.3 (82.0–93.0) 55 (4.4) 85.0 (76.0–95.2)
IIIA 121 (9.7) 81.3 (74.5–88.7) 59 (4.7) 77.6 (67.6–89.1)
IIIB – – 57 (4.6) 67.7 (56.5–81.2)
IIIC 66 (5.3) 70.5 (50.2–82.6) – –
Abbreviations: N number, yr year, DDFS distant disease-free survival
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Previous studies in general BC patient populations have
described a reallocation rate with prognostic stage most
frequently reported around 40–60% (range 18–74%;
Additional file 1) [7, 9–23]. In the California Cancer
Registry, including 54,727 patients in anatomic stages I
to IV, 31.0% and 20.6% of patients were assigned to a
more favorable and less favorable stage category with
prognostic stage, respectively [7]. Only a few studies re-
ported the discrepancy between the two stage models
specifically for HER2-positive BC patients, leading to
non-univocal results (Additional file 1) [9, 14, 21, 23]. A
large cohort from the National Cancer Database includ-
ing n = 60,155 HER2-positive BC patients showed 29.4%
and 0% rates of downstaging and upstaging, respectively
[9]. Another study showed that 35.8% and 40.7% of
HER2-positive patients (n = 1982) were classified as stage
I by anatomic stage and prognostic stage, respectively
[15]. The rate of downstaging (58.4%) was higher in our
study, and consequently, the enrichment in stage I pa-
tients with prognostic stage was also more evident. The
high prevalence of hormone receptor-positive patients in
the ShortHER population (68%) might have contributed
to substantial downstaging. It should be highlighted that
the ShortHER population reflects the characteristics of
HER2-positive patients commonly treated in contempor-
ary clinical practice [25, 27].
Our data show that the substantial downstaging of pa-
tients with the prognostic stage did not affect the perform-
ance of the model which was maintained similar to
anatomic stage (P = 0.975 for C index comparison). In this
context, available literature data focused on HER2-positive
patients are scanty. Moreover, their interpretation is ex-
tremely limited by the lack of homogenous treatment or
lack of information about it (Additional file 1) [18, 23].
The largest cohort of HER2-positive patients analyzed for
survival outcome according to prognostic stage included
562 cases (mostly not treated with trastuzumab) and
showed a good 10-year disease-specific survival for prog-
nostic stage I patients (> 96%), but did not report overall
model performance [18].
As previously discussed, prognostic stage led to an en-
richment in stage I (70% vs 40.9% anatomic stage) and
more specifically in stage IA patients (58.9% vs 37.7%).
The pairwise comparisons conducted in stage I–IIA pa-
tients suggest that the prognostic stage better discrimi-
nated the group of patients with the best prognosis
among others (IA), whereas with anatomic stage there
Fig. 1 Kaplan-Meier DDFS curves by anatomic stage (a) and prognostic stage (b)
Table 4 Cox regression DDFS analysis
Anatomic stage Prognostic stage
HR (95%CI) P HR (95%CI) P
IA Ref Ref
IB 0.93 (0.22–3.92) 0.917 2.02 (1.12–3.64) 0.020
IIA 1.60 (0.95–2.71) 0.079 2.36 (1.45–3.85) 0.001
IIB 3.02 (1.68–5.42) < 0.001 2.78 (1.31–5.93) 0.008
IIIA 4.14 (2.35–7.29) < 0.001 4.50 (2.46–8.24) < 0.001
IIIB – – 8.8 (5.33–14.54) < 0.001
IIIC 8.58 (4.90–15.02) < 0.001 – –
Abbreviations: HR hazard ratio, CI confidence interval, P P value
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was no significant difference in outcome among patients
in stages IA, IB, and IIA. However, when looking at ab-
solute survival rates, stage IA patients had slightly nu-
merically inferior outcome as compared to stage IA
groups by anatomical stage. The numerically worse out-
come for prognostic stage and matched anatomic stage
categories was evident for all stage groups. In synthesis,
the prognostic stage, by recognizing the prognostic effect
of biomarkers, results in a shift from a worse to a better
stage category (mostly to stage IA or stage IB) of a large
number of patients as compared to the anatomic stage.
One of the consequences of this shift is a better separ-
ation of stage groups in terms of DDFS, especially in
stage I–IIA patients. However, intuitively, in absolute
terms, the outcome of prognostic stage IA and IB pa-
tients, being enriched by patients with a worse anatomic
stage category, is somehow diluted and results numeric-
ally inferior to the corresponding anatomic stage. More-
over, prognostic stage > IIA categories are depleted vs
the same anatomic stage category in patients with a bet-
ter prognosis; again, as a consequence, the outcome of
prognostic stage > IIA groups is numerically inferior to
the corresponding anatomic stage. The main implication
is that the prognostic stage is more valuable as anatomic
stage as a tool to counsel patients about their prognosis:
by applying the prognostic stage, more patients would
be regrouped in more favorable stage categories and
would be informed about a good outcome as compared
to the anatomic stage. To the other side, the prognostic
stage identifies a more restricted number of patients
with far poorer outcomes. However, what clinicians have
to keep in mind when counseling patients is that in
absolute terms the estimated outcome for a given prog-
nostic stage category might not correspond to the esti-
mation for the same anatomic category.
An appropriate identification of patients at excellent
outcome with standard adjuvant treatment is key to
identifying those patients who may be offered de-
escalated treatment strategies. Treatment de-escalation
for HER2-positive patients with anthracycline-free
regimens as the paclitaxel-trastuzumab schedule is
already administered in clinical practice based on ana-
tomic stage, mostly for patients with stage I disease
[28, 29]. We explored whether prognostic stage I may
be of value in identifying patients for de-escalated
therapies. Our results suggest that if anatomic stage I
seems a good parameter to guide de-escalated thera-
peutic choices, this may not be the case for prognos-
tic stage I. Indeed, prognostic stage I patients treated
with short trastuzumab had an absolute 3% worse
DDFS rate at 5 years as compared to patients enrolled
in the long trastuzumab arm. When restricting the
analysis to prognostic stage IA, there was still an ab-
solute 1.5% difference in 5-year DDFS favoring the
long arm. However, this result was not statistically
significant and was based on a difference of just six
events between the two arms. Although these were
exploratory, unplanned, and unpowered analyses that
should be interpreted with caution, the results can be
considered as hypothesis-generating that require fur-
ther testing in similar trials. To note, the acceptable
absolute difference in outcome to consider a de-
escalated treatment as safe is currently debated [30].
If our results will be confirmed in further studies, the
two staging systems will be recognized as providing
divergent information in the context of patient selec-
tion for treatment de-escalation, possibly posing a
challenge in the implementation of the prognostic
stage in clinical practice.
Our study has strengths: this is the first study evaluat-
ing the prognostic performance of prognostic stage in a
cohort of HER2-positive patients, all receiving chemo-
therapy and trastuzumab; patient population is derived
from a prospective trial; 99% of patients had sufficient
Fig. 2 Kaplan-Meier DDFS curves for patients treated in the short (9 weeks trastuzumab) vs the long (1 year trastuzumab) arm according to stage
categories: anatomic stage I patients (a), prognostic stage I patients (b), prognostic stage IA patients (c)
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data for the present analysis; the study design allowed to
explore short vs long trastuzumab in stage-defined
groups.
Main limitations of this study include the choice of
the survival endpoint (DDFS) which is different from the
one used to develop and validate the prognostic stage
(BC-specific survival) [7]. In the ShortHER trial, actual
median follow-up does not allow for a mature evaluation
of BC-specific survival in this population of patients.
Therefore, we opted to use DDFS as a surrogate of
BC-specific survival considering the lethal nature of
DDFS events. Another limitation is the reduced sample
size in stage-defined groups, limiting the power of direct
comparisons.
Conclusions
In conclusion, the AJCC prognostic stage is valuable in
counseling patients regarding their prognosis and may
serve as reference for clinical trial design and sample size
estimation. Our data do not support the assumption that
prognostic stage may also guide treatment de-escalation,
thus more information from other randomized trials are
needed. These findings fill the present void of appraising
the clinical validity and utility of prognostic staging in
HER2-positive patients. Research into integrated models
of risk stratification tailored at fulfilling the need for
clinically useful tools to guide de-escalated therapeutic
choices is highly encouraged.
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